Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,525 JPY | +0.26% | -1.26% | -9.55% |
Sales 2024 | 1,604B 10.26B | Sales 2025 * | 1,656B 10.6B | Capitalization | 2,727B 17.45B |
---|---|---|---|---|---|
Net income 2024 | 17.04B 109M | Net income 2025 * | 94.35B 604M | EV / Sales 2024 | 1.84 x |
Net Debt 2024 * | 503B 3.22B | Net Debt 2025 * | 512B 3.28B | EV / Sales 2025 * | 1.96 x |
P/E ratio 2024 |
173
x | P/E ratio 2025 * |
29
x | Employees | 14,484 |
Yield 2024 |
4.26% | Yield 2025 * |
4.94% | Free-Float | 98.83% |
Latest transcript on Astellas Pharma Inc.
1 day | +0.26% | ||
1 week | -1.26% | ||
Current month | +0.73% | ||
1 month | +5.46% | ||
3 months | -7.72% | ||
6 months | -13.89% | ||
Current year | -9.55% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 21-05-31 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 17-05-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 19 M€ | +11.51% | ||
2.09% | 240 M€ | +15.33% | ||
2.01% | 60 M€ | +21.62% | ||
1.99% | 10 M€ | +14.50% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 1,525 | +0.26% | 4 901 000 |
24-05-14 | 1,521 | +0.70% | 6,123,400 |
24-05-13 | 1,510 | -1.11% | 4,597,000 |
24-05-10 | 1,528 | -0.88% | 6,638,000 |
24-05-09 | 1,541 | -0.23% | 5,938,700 |
Delayed Quote Japan Exchange, May 15, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.55% | 17.43B | |
+31.06% | 688B | |
+30.35% | 588B | |
-3.42% | 364B | |
+18.02% | 326B | |
+4.27% | 285B | |
+15.53% | 239B | |
+10.16% | 210B | |
-8.14% | 200B | |
+8.12% | 167B |
- Stock Market
- Equities
- 4503 Stock